<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<DRUG name="FUSIDIC ACID" rxcui="4608">
<ATC code="D06AX01" />
<ATC code="D09AA02" />
<ATC code="J01XC01" />
<ATC code="S01AA13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Stop the treatment with the HMG Co-A reductase inhibitor before starting a treatment with fusidic acid or use another antibiotic</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring, especially at the beginning of the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<DRUG name="DAPTOMYCIN" rxcui="22299">
<ATC code="J01XX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of addition of the undesirable effects (dose dependent) of the rhabdomyolysis type.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these medications together cannot be avoided, reinforce biological monitoring (dosage of the CPK more than once a week) and strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<DRUG name="ELTROMBOPAG" rxcui="711942">
<ATC code="B02BX05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the statins, due to inhibition of their hepatic recapture</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the statin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<CLASS name="FIBRATES" code="C01AB-001" /></DRUG2>
<DESCRIPTION>Risk of addition of undesirable effects (dose-dependent) of the rhabdomyolosis type. Furthermore, with the gemfibrozil, decrease of the metabolism of the simvastatin and of the rosuvastatin, which increases the muscular risk, as well as the nephrotoxicity of the rosuvastatin</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with the gemfibrosil and the simvastatin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the statin and of its undesirable effects of the rhabdomyolosis type.</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with the rosuvastatin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<DRUG name="LENALIDOMIDE" rxcui="342369">
<ATC code="L04AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of the onset of rhabdomyolysis</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce clinical and biological monitoring, especially during the first weeks of treatment.</COMMENT>
</INTERACTION>
</INTERACTIONS>
